Prostaglandin J2 (PGJ2), a derivative of Prostaglandin D2 (PGD2), serves as a potent agonist for PGD2 receptors (DP), exhibiting affinity constants (K i) of 0.9 nM and 6.6 nM for hDP and hCRTH2 receptors, respectively. It activates cyclic AMP production with an EC50 of 1.2 nM, induces oxidative stress, neuronal apoptosis, and promotes the accumulation of ubiquitinated (Ub) proteins. Notably, PGJ2's neurotoxic properties are implicated in the progression of neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD) [1] [2] [3] [4].

DP receptor (human):0.9 nM (Ki), EP2 receptor (human):989 nM (Ki), FPR (human):553 nM (Ki), EP3 receptor (human):319 nM (Ki), hEP4:1065 nM (Ki), IP (human):>25 μM (Ki), EP1 (human):15.678 μM (Ki), CRTH2 (human):6.6 nM (Ki), TP Receptor (human):6426 nM (Ki)